[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-341586-105":59,"doc-detail-341586-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","senescence-in-the-bone-marrow-microenvironment-a-driver-in-development-of-therapy-related-myeloid-neoplasms","Senescence in the bone marrow microenvironment - A driver in development of therapy-related myeloid neoplasms","","Therapy-related myeloid neoplasms (t-MN) are increasing as cytotoxic cancer treatments remain widely used. Cytotoxic therapies can induce therapy-induced senescence in normal tissues, including the bone marrow microenvironment (BMME), which supports hematopoiesis. This review synthesizes recent evidence linking BMME senescence to t-MN pathogenesis and outlines therapeutic intervention opportunities aimed at intervening in this biology, including strategies that target senescent cells to improve outcomes.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/senescence-in-the-bone-marrow-microenvironment-a-driver-in-development-of-therapy-related-myeloid-neoplasms/341586/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/senescence-in-the-bone-marrow-microenvironment-a-driver-in-development-of-therapy-related-myeloid-neoplasms/341586.png","ImageObject",300,407,{"name":92,"@type":93},"Ezra","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-01","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",14,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why are therapy-related myeloid neoplasms (t-MN) an increasing concern?","Question",{"text":113,"@type":114},"t-MN incidence is rising with the continued use of cytotoxic therapies and radiotherapy, alongside improved survival that expands the window for secondary disease development.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What role does the bone marrow microenvironment (BMME) play in t-MN development?",{"text":118,"@type":114},"Cytotoxic therapy can drive senescence within the BMME, and current studies support BMME senescence as a contributor to the initiation and progression of t-MN.",{"name":120,"@type":111,"acceptedAnswer":121},"How might targeting senescent cells help mitigate t-MN?",{"text":122,"@type":114},"The review highlights that targeting senescent bone marrow stromal cells may alleviate bone marrow dysfunction and help mitigate therapy-related myeloid neoplasms.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},341586,1790090003,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099514068035,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","J BONE ONCOL 47 (2024) 100620  \nContents lists available at ScienceDirect Journal of Bone Oncology  \njournal [homepage:](homepage: www.elsevier.com/locate/jbo)[ www.elsevier.com/locate/jbo](homepage: www.elsevier.com/locate/jbo)  \n| Senescence in the bone marrow microenvironment: A driver in development of therapy-related myeloid neoplasms\u003Cbr>Angelo Jose Guilatcoa, b , Mithun Vinod Shah a , Megan Moore Weivoda a, *\u003Cbr>a Division of Hematology, Mayo Clinic, Rochester, MN, USA\u003Cbr>b Cancer Biology Program, University of Michigan, Ann Arbor, MI, USA |  |\n| --- | --- |\n| H I G H L I G H T S |  |\n| • Cytotoxic therapy increases the risk for therapy-related myeloid neoplasms (t-MN).\u003Cbr>• While HSC-intrinsic effects are crucial, t-MN is also dependent on extrinsic factors.\u003Cbr>• Cytotoxic therapy drives senescence in the bone marrow microenvironment (BMME).\u003Cbr>• Current studies support a role for BMME senescence in the development of t-MN.\u003Cbr>• Targeting of senescent BMSCs may alleviate BM dysfunction and mitigate t-MN. |  |\n| A R T I C L E I N F O\u003Cbr>Keywords:\u003Cbr>Senescence Myeloid neoplasm Clonal hematopoiesis\u003Cbr>Bone marrow microenvironment\u003Cbr>Bone marrow stromal cell Senolytics | A B S T R A C T |\n|  | Therapy-related myeloid neoplasms (t-MN) are a growing concern due to the continued use of cytotoxic therapies to treat malignancies. Cytotoxic therapies have been shown to drive therapy-induced senescence in normal tissues, including in the bone marrow microenvironment (BMME), which plays a crucial role in supporting normal hematopoiesis. This review examines recent work that focuses on the contribution of BMME senescenceto t-MN pathogenesis, as well as offers a perspective on potential opportunities for therapeutic intervention. |\n\n1. Introduction  \nThe last two decades have seen a remarkable expansion of novel, anti-neoplastic agents, including immunomodulators and targeted therapies, that have helped to reduce cancer mortality rates. However, for many malignant conditions, standard of care continues to involve the administration of cytotoxic chemotherapies (e.g., alkylating agents, platinum agents, antimetabolites, topoisomerase inhibitors, Vinca alkaloids, and other antineoplastics) and/or radiotherapy which induce cell death in tumor cells by exploiting their accelerated replication and metabolic differences compared to normal cells. Despite their ability to slow or ablate cancer progression, these agents lack complete selectivity for tumor cells, and their non-specific toxicity invariably affects healthy cells and disrupts normal tissue homeostasis, increasing the risk formorbidities and secondary malignancies [1,2]. For certain early-stage, non-metastatic cancers, off-target cytotoxicity can be prevented by local or targeted delivery. Unfortunately, this is often not possible for  \nadvanced, metastatic disease or systemic hematologic malignancies. Furthermore, the use of high-dose cytotoxic drugs (e.g., melphalan, cyclophosphamide) or radiotherapy as conditioning agents prior to autologous/allogeneic bone marrow transplant or chimeric antigen receptor (CAR)T-cell therapy in cancer patients requires these cytotoxic effects within normal cells in the bone marrow microenvironment (BMME) for successful engraftment; this profound impact on the BMME, the primary site of hematopoiesis, puts these patients at risk for secondary, therapy-related myeloid neoplasms (t-MNs) [3].  \nMyeloid neoplasms are clonal hematopoietic stem cell (HSC) disorders characterized by the expansion of abnormal hematopoietic cells and a paucity of normal hematopoiesis. While myeloid neoplasms can arise de novo, t-MNs arising following therapy (i.e., exposure to chemotherapy or radiotherapy for an antecedent condition [4]) represent a significant portion of newly diagnosed myeloid neoplasms. The incidence of t-MNs is rising and expected to continue to grow due to the increasing aging population, the increased use of DNA-damaging  \n* Corresponding author at: 2","cbCaim9pkmXn80eh","https://ap.wps.com/l/cbCaim9pkmXn80eh","pdf",1282128,"English","# Highlights\n## Cytotoxic therapy and t-MN risk\n## Role of BMME senescence\n## Therapeutic targeting of senescent bone marrow stromal cells\n# Introduction\n## Limitations of cytotoxic selectivity\n## Conditioning regimens and secondary t-MNs\n## Myeloid neoplasms and clonal hematopoietic stem cell disorders\n# Myeloid neoplasms\n## Relationship between MDS and AML\n## Clinical manifestations: dysplasia, cytopenias, morbidity","[{\"question\":\"Why are therapy-related myeloid neoplasms (t-MN) an increasing concern?\",\"answer\":\"t-MN incidence is rising with the continued use of cytotoxic therapies and radiotherapy, alongside improved survival that expands the window for secondary disease development.\"},{\"question\":\"What role does the bone marrow microenvironment (BMME) play in t-MN development?\",\"answer\":\"Cytotoxic therapy can drive senescence within the BMME, and current studies support BMME senescence as a contributor to the initiation and progression of t-MN.\"},{\"question\":\"How might targeting senescent cells help mitigate t-MN?\",\"answer\":\"The review highlights that targeting senescent bone marrow stromal cells may alleviate bone marrow dysfunction and help mitigate therapy-related myeloid neoplasms.\"}]","Senescence in the bone marrow microenvironment - A driver in development of therapy-related myeloid neoplasms | PDF",1790042677,23,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c8840bdfd521a854c89c7ed8f5dc7726.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/72501b4cb9af9e3c0bd6d69d3c91e8b6.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2689b1dae4cb9678a7dfc089f2839e7d.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/88b018fa15d19acf8b924ac959334286.webp",980,1306]